ADVANZ PHARMA

#News for #investors and #media: ADVANZ PHARMA has expanded its specialty brands portfolio by acquiring certain APAC (excluding Japan and China) rights to a specialty medicine from Bayer. This strategic move underscores our commitment to leveraging our commercial footprint and global partner network to bring innovative treatments to patients worldwide. More details here: https://bit.ly/3B56fOO #partnerofchoice #growth #specialtypharma

This week marks the 5th annual Global Biosimilars Week, a campaign first launched in 2020 by the International Generic and Biosimilars Medicines Association. ADVANZ PHARMA supports the celebration of rapid advancements in biosimilar medicines and their important role in improving patient access to biologic medicines. Within the last two years, ADVANZ PHARMA has entered strategic partnerships to commercialise eight proposed biosimilar medicines in Europe across multiple therapeutic areas, including rheumatology, gastroenterology, ophthalmology, respiratory and rare disease. To find out more information about ADVANZ PHARMA, our commitment to expanding patient access, and our mission to be the partner of choice bit.ly/4fIKT8v #GlobalBiosimilarsWeek #PartnerofChoice

#News for #investors and #media: ADVANZ PHARMA has expanded its specialty brands portfolio through the acquisition of two CNS brands for Europe and selected countries in LATAM and APAC. This acquisition reflects our commitment to growing our global specialty brands portfolio, leveraging our commercial and medical presence in Europe and our extensive distribution network worldwide. By strengthening our portfolio, we continue to support healthcare professionals and provide vital medications that enhance patient care. More details here: https://bit.ly/4eeDUTx #partnerofchoice #growth #specialtypharma

ADVANZ PHARMA will be attending CPHI 2024 in Milan, one of the world’s most influential events for the pharmaceutical industry. This global gathering provides the perfect platform for innovation, networking, and forging meaningful collaborations. As a company dedicated to improving patients’ lives by providing the specialty, hospital, and rare disease medicines they depend on, we look forward to sharing insights, exploring new partnerships, and discussing the future of healthcare with industry leaders and innovators. Looking forward to seeing you at stand 10F48! #CPHI2024 #PharmaInnovation #SpecialtyPharma #PharmaIndustry

#News for #investors and #media: ADVANZ PHARMA and Enzene enter an exclusive partnership for biosimilar development and commercialisation. This partnership underscores our commitment to bring impactful therapies to market. By leveraging Enzene's development capabilities, we aim to improve access to a valuable treatment option, reinforcing our position as a partner of choice for commercialisation of specialty and rare disease medicines in Europe. More details here: bit.ly/3yWq2ik #partnerofchoice #growth #specialtypharma

#News for #investors and #media: ADVANZ PHARMA secures rights to commercialise Alvotech’s biosimilar candidate in Europe. We are excited to reinforce our collaboration with Alvotech by adding an impactful and meaningful product to our growing pipeline. This partnership leverages our combined strengths and reinforces ADVANZ PHARMA as a partner of choice for the commercialisation of specialty pharmaceuticals in Europe. More details here: bit.ly/3KMkclO #partnerofchoice #growth #specialtypharma

We're excited to participate in the Global Steps Challenge as part of Mental Health Awareness Week. At ADVANZ PHARMA, we understand the importance of prioritising mental well-being, and we're stepping up to show our support. Throughout this week, our team members around the globe will be taking steps to raise awareness for mental health. Whether walking, running, or hiking, every step brings us closer to fostering a healthy workplace culture. #MentalHealthAwarenessWeek #StepForwardForWellness 

Our #ThisIsADVANZPHARMA series continues! Today, we're thrilled to introduce Daniel West, Vice President Business Development & Licensing, who's been with us since 2018. Daniel joined ADVANZ PHARMA with a clear mission: to support our growth as a patient-centric organisation. He explains: "Every day, I get to work on innovations that could fill unmet medical needs and make a real difference in the lives of patients. It's rewarding to play a pivotal role in bringing groundbreaking, value-added medicines to market." What keeps Daniel excited? "The passion and creativity of my colleagues and peers. We're all committed to enhancing healthcare systems, harmonising development and regulatory processes, and using technology to engage clinicians more effectively. It's this energy that makes ADVANZ PHARMA a great place to work." #ThisIsADVANZPHARMA #OneTeam #Innovation

We are excited about the very high employee engagement at ADVANZ PHARMA – as evidenced by our most recent staff survey. Thanks to all our colleagues who took the time to participate in this survey. The overwhelming response rate of 91% speaks volumes about the strong engagement within our teams. Among the survey findings, one of the standout results is the sense of pride our employees feel about being part of ADVANZ PHARMA, with 86% expressing their willingness to recommend us as a great place to work. Furthermore, we're proud of the high scores in areas such as clarity and progress toward our strategic goals, confidence in achieving our ambitions, teamwork, and collaboration, which are significantly above industry benchmarks. Here's to continued growth and success together! #EmployeeEngagement #Teamwork #SuccessStory

ADVANZ PHARMA announces the European Commission (EC) granted marketing authorisation in the European Union for a novel intravenous antibiotic. This antibiotic will be marketed in the European Union, the United Kingdom, Switzerland, and Norway by ADVANZ PHARMA under a license and supply agreement closed with Allecra Therapeutics in 2022. ADVANZ PHARMA is committed to improving patients’ lives by providing potent therapeutic options in Europe in areas with high patient need. Read more: bit.ly/3IUMwl1 #pharmaceuticals #partnerofchoice #patients